73 related articles for article (PubMed ID: 12454701)
21. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
22. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
[TBL] [Abstract][Full Text] [Related]
23. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.
Kitagawa M; Yoshida S; Kuwata T; Tanizawa T; Kamiyama R
Am J Pathol; 1994 Aug; 145(2):338-44. PubMed ID: 8053492
[TBL] [Abstract][Full Text] [Related]
24. Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases.
Qian J; Chen Z; Lin J; Wang W; Cen J
Leuk Res; 2005 Dec; 29(12):1435-41. PubMed ID: 16005964
[TBL] [Abstract][Full Text] [Related]
25. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
Hofmann WK; Takeuchi S; Takeuchi N; Thiel E; Hoelzer D; Koeffler HP
Leuk Res; 2006 Nov; 30(11):1347-53. PubMed ID: 16682076
[TBL] [Abstract][Full Text] [Related]
27. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
28. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
29. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
[TBL] [Abstract][Full Text] [Related]
30. Expression of P2X7 in human hematopoietic cell lines and leukemia patients.
Zhang XJ; Zheng GG; Ma XT; Yang YH; Li G; Rao Q; Nie K; Wu KF
Leuk Res; 2004 Dec; 28(12):1313-22. PubMed ID: 15475073
[TBL] [Abstract][Full Text] [Related]
31. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic recovery after IEV chemotherapy for malignant lymphoma followed by different cytokines can be monitored by analysis of Galpha 16 and CD34.
Pfeilstöcker M; Karlic H; Salamon J; Mühlberger H; Pavlova B; Strobl H; Pittermann E; Heinz R
Am J Hematol; 2000 Jul; 64(3):156-60. PubMed ID: 10861809
[TBL] [Abstract][Full Text] [Related]
33. Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays.
Lee YT; Miller LD; Gubin AN; Makhlouf F; Wojda U; Barrett AJ; Liu ET; Miller JL
Blood; 2001 Sep; 98(6):1914-21. PubMed ID: 11535529
[TBL] [Abstract][Full Text] [Related]
34. Understanding the pathogenesis of myelodysplastic syndromes.
Delforge M
Hematol J; 2003; 4(5):303-9. PubMed ID: 14502253
[TBL] [Abstract][Full Text] [Related]
35. DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome.
Ueda M; Ota J; Yamashita Y; Choi YL; Ohki R; Wada T; Koinuma K; Kano Y; Ozawa K; Mano H
Br J Haematol; 2003 Oct; 123(2):288-96. PubMed ID: 14531911
[TBL] [Abstract][Full Text] [Related]
36. MDS and secondary AML: an evolutionary perspective.
Audeh MW
Cancer Treat Res; 2001; 108():267-78. PubMed ID: 11702604
[No Abstract] [Full Text] [Related]
37. Induction of erythroid differentiation by altered Galpha16 activity as detected by a reporter gene assay in MB-02 cells.
Ghose S; Porzig H; Baltensperger K
J Biol Chem; 1999 Apr; 274(18):12848-54. PubMed ID: 10212272
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathogenesis and targets for therapy in myelodysplastic syndrome (MDS) and MDS-related leukemias.
Karp JE
Curr Opin Oncol; 1998 Jan; 10(1):3-9. PubMed ID: 9466478
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathogenesis of MDS.
Hirai H
Int J Hematol; 2002 Aug; 76 Suppl 2():213-21. PubMed ID: 12430928
[TBL] [Abstract][Full Text] [Related]
40. The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia.
Steensma DP
Haematologica; 2007 Jun; 92(6):723-7. PubMed ID: 17550842
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
